2020 | |
---|---|
Criterium: | Position: |
Overall Score: | > 1000 |
Total Project Funding per Partner: | > 1000 |
Total Number of Projects: | > 1000 |
2016 | |
Criterium: | Position: |
Overall Score: | > 1000 |
Networking Rank (Reputation): | > 1000 |
Total number of projects: 7
As coordinator: 0
As participant: 7
Sole participant: 0
Coordinator / Participant Ratio: 0*
Total project funding [€]: | Projects [No]: | |||||
---|---|---|---|---|---|---|
Year: | coordinator* | participant* | per partner | as coordinator | as participant | |
2022 | 0 | 6.549.674 | 480.000 | 1 | ||
2020 | 0 | 27.435.615 | 1.789.448 | 3 | ||
2017 | 0 | 1.102.500 | 0 | 1 | ||
2016 | 0 | 23.215.937 | 718.968 | 2 |
Total number of partners: 138
Partner loyalty:
Frequent Partner: (> 2 projects): 15
Rare Partner: 123
Frequent / Rare Partner Ratio: 0.12
Start date | Project | acronym | role | funding | partners |
---|---|---|---|---|---|
2022-06-01 | Decision support for prediction and management of Long Covid Syndrome (LCS) | Long Covid | participant | 6.549.674 | 12 |
2020-06-01 | Stratification of Obesity Phenotypes to Optimize Future Therapy | SOPHIA | participant | 8.301.000 | 36 |
2020-03-01 | Advancing Innovative Stem Cell-based Therapy for Diabetes in Europe | ISLET | participant | 7.999.999 | 8 |
2020-01-01 | Impact of exposome on the course of lung diseases | REMEDIA | participant | 11.134.616 | 17 |
2017-03-01 | Genetic and Small Molecule Modifiers of Lysosomal Function | LysoMod | participant | 1.102.500 | 14 |
2016-09-01 | Biomarker Enterprise to Attack DKD - Sofia ref.: 115974 | BEAt-DKD | participant | 15.085.937 | 31 |
2016-04-01 | Assessing risk and progression of prediabetes and type 2 diabetes to enable disease modification - Sofia ref.: 115881 | RHAPSODY | participant | 8.130.000 | 27 |